Alamar Biosciences, Inc. Convertible Debt
Alamar Biosciences, Inc. (ALMR) had Convertible Debt of $65.09 million as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ConvertibleDebt · last filed 2026-08-11
- 2026-03-31: Convertible Debt $65.09M.
- 2026-01-08: Convertible Debt $56.50M.
| Period end | Convertible Debt |
|---|---|
| 2026-03-31 | $65.09M 10-Q · filed 2026-05-08 |
| 2026-01-08 | $56.50M 10-Q · filed 2026-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |